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Glypican-3 (gpc3) is the gene responsible for Simpson-Golabi-
Behmel overgrowth syndrome. Previously, we have shown that
GPC3 is overexpressed in hepatocellular carcinoma (HCC). In
this study, we demonstrated the mechanisms for GPC3-mediated
oncogenesis. Firstly, GPC3 overexpression in NIH3T3 cells gave
to cancer cell phenotypes including growing in serum-free me-
dium and forming colonies in soft agar, or on the other way,
GPC3 knockdown in HuH-7 cells decreased oncogenecity. We
further demonstrated that GPC3 bound speciﬁcally through its
N-terminal proline-rich region to both Insulin-like growth factor
(IGF)-II and IGF-1R. GPC3 stimulated the phosphorylation of
IGF-1R and the downstream signaling molecule extracellular sig-
nal-regulated kinase (ERK) in an IGF-II-dependent way. Also,
GPC3 knockdown in HCC cells decreased the phosphorylation
of both IGF-1R and ERK. Therefore, GPC3 confers oncogenecity
through the interaction between IGF-II and its receptor, and the
subsequent activation of the IGF-signaling pathway. This data are
novel to the current understanding of the role of GPC3 in HCC
and will be important in future developments of cancer therapy.
Introduction
Hepatocellular carcinoma (HCC) is the leading cause of death among
cancersinmanycountriesespeciallyinAsia,andtheincidenceofHCC
is rising in many other countries (1,2). The molecular mechanisms for
hepatocarcinogenesis are quite complex (3), and despites early detec-
tion and aggressive therapies, the outcome of HCC remains grave. We
previously discovered that glypican-3(GPC3, also known as MXR7) is
overexpressed in HCC (4). gpc3 mRNA was detectable in 143 of 191
(74.8%)primaryandrecurrentHCCs,whereasonlyin3.2%ofthenon-
tumor part of the livers. GPC3 overexpression correlates to high alpha-
fetoprotein, high tumor grade and high tumor aggressiveness in HCC
individuals (4), and GPC3 stimulates in vitro and in vivo growth of
HCC (5).Overexpressionofgpc3mRNA isalsoobservedinmetastatic
colorectal carcinomas (6), alpha-fetoprotein-producing gastric carci-
noma (7), hepatoblastoma, Wilms’ tumor (8), malignant melanoma
(9), yolk sac tumor, choriocarcinoma (10), ovarian carcinoma (11)
and in cell lines derived from breast cancer (12) and ovarian cancer
(13). These ﬁndings suggest that GPC3 plays a role in oncogenesis.
GPC3 is a glycosyl-phosphatidylinositol-anchoring heparan sulfate
proteoglycan (14). It functions as a ‘coreceptor’ for heparin-binding
proteins like growth factors or adhesion molecules (15,16), and the
binding of coreceptors facilitate interactions between the heparin-
binding factors and their corresponding receptors (17,18). GPC3 is
ﬁrst processed to the 65 kDa core protein, which can be further
cleaved by a furin-like convertase into a 40 kDa protein. GPC3 mod-
ulates Wnt signaling and stimulates the growth of HCC cells in a gly-
cosaminoglycan-independent way (5). GPC3 has also been reported
to bind Insulin-like growth factor-II (19,20). The IGF-signaling path-
way plays a pivotal role in cell proliferation (21), G1 cell cycle pro-
gression (22), prevention of apoptosis (23) and the initiation and
maintenance of oncogenesis (24–26). Increase in IGF-II expression
has been observed in liver cancers including HCC (27–29), and in-
sulin receptor substrate-1, an adapter molecule for IGF-II signaling, is
overexpressed in HCC (30,31). GPC3 is also involved in the pathogen-
esis of Simpson-Golabi-Behmel overgrowth syndrome (19,20).
In order to study the mechanism for GPC3-mediated oncogenesis,
weexpressedGPC3inGPC-nullNIH3T3cellsandalsoknockeddown
GPC3 in GPC3-expressing HCC cells. We demonstrated speciﬁc
interactions both between GPC3 and IGF-II and between GPC3 and
IGF-IR, and we also showed GPC3- and IGF-II-dependent phosphor-
ylation of IGFI-R and extracellular signal-regulated kinase (ERK).
Therefore, GPC3 confers oncogenecity through interacting with
IGF-IIanditsreceptorandtheactivationoftheIGF-signalingpathway.
Materials and methods
Cell lines
HEK293, HEK293T, HeLa, PLC-PRF-5 (American Tissue Cell Collection),
NIH3T3 (Biosources Collection and Research Center, National Health Re-
search Institute, Taiwan), HA22T/VGH (32) and HuH-7 (33) cells were cul-
tured in Dulbecco’s modiﬁed Eagle’s medium supplemented with 10% fetal
bovine serum. All cell lines were maintained at 37C in a humidiﬁed atmo-
sphere with 5% CO2. Serum starvation was done in 0.5% serum for the
HA22T/VGH cells and was in 0% serum for all other cells.
Plasmids
Thewild-typeGPC3expressionvectorpcDNA-gpc3wasconstructedbyinserting
gpc3 complementary DNA into pcDNA3.1 (þ) myc-his vector (Invitrogen, San
Diego, CA) (4). The C-terminal green ﬂuorescence protein (GFP)-tagged GPC3
(GPC3-GFP) expression vector pgpc3-GFP was constructed by replacing the
stop codon with an EcoRI site (using primer T3 and GTGCTTCT-
TCTTCCTGGTGAAGGCTGGTGAATTCT, with the EcoRI site underlined),
and transferred into pcDNA3.1. KpnI/EcoRV fragment of the insert was trans-
ferred into KpnI and SmaI site of pEGFP-N1 vector (Clontech, Mountain View,
CA).Arginineresidues355and358oftheGPC3proteinweremutatedtoalanine
by site-directed mutagenesis to express GPC3 mutant RR / AA (RR / AA)
(34); and proline residues 25–29 were mutated to alanine in GPC3 mutant P25-
29A (P25-29A). All constructs were conﬁrmed by DNA sequencing.
Transfection and selection for stable lines
Transient transfection was done with Lipofectamine 2000 according to the
manufacturer’s instruction (Invitrogen). To generate NIH3T3, PLC-PRF-5
Abbreviations: ERK, extracellular signal-regulated kinase; GFP, green ﬂuo-
rescence protein; GPC3, glypican-3; GST, glutathione S-transferase; HCC,
hepatocellular carcinoma; IGF, insulin-like growth factor; shRNA, small
hairpin RNA; siRNA, small interfering RNA; mRNA, messenger RNA.
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(Invitrogen). Surviving cells were isolated and expanded.
Reverse transcription-polymerase chain reaction
Total RNA was extracted by the Trizol reagent (Invitrogen) and was reverse
transcribed according to the manufacturer’s instruction (Invitrogen). Semiquan-
titative reverse transcription–polymerase chain reaction was used to measure
gpc3 mRNA levels using primers GPC3-974-F (TGCTCTTACTGCCAGG-
GACT) and GPC3-1671-R (TCAAACCCTTCCTCATCCAG).For checking hu-
man IGF-1 mRNA, hIGF-1-F (ATGGGAAAAATCAGCAGTCT) and hIGF-1-R
(CATCCTGTAGTTCTTGTTTCC) were used. For checking murine IGF-1
mRNA,mIGF-1-F(CATGTCGTCTTCACACCTCTT)andmIGF-1-R(CTTGT-
GTTCTTCAAATGTA) were used. For checking human IGF-II mRNA, hIGF-II-F
(ATGGGAATCCCAATGGGGAA) and hIGF-II-R (CTCGGACTTGGCGG-
GGGTA) were used.For checking murine IGF-IImRNA,mIGF-II-1255-F(CGC
TTAGTTTGTCTGTTCG) and mIGF-II-1597-R (CGTTTGGCCTCTCTGAA-
CTC) were used.
Antibodies and immunoprecipitation assay
Antibodies used included anti-GPC3 (1G12, BioMosaics, Burlington, VT),
anti-GFP (Clontech), anti-tubulin, anti-actin (Sigma–Aldrich, St Louis, MO),
anti-phosphotyrosine (PY20) (Upstate Cell Signaling Solutions, Lake Placid,
NY), anti-IGF-1Rb, anti-phospho-ERK1/2, anti-phospho-IGF-1Rb (Tyr1135/
1136) (Cell Signaling Technology, Danvers, MA), anti-ERK1/2 and anti-
glutathione S-transferase (Santa Cruz Biotechnology, Santa Cruz, CA). The
anti-CC3 antibody was raised in rabbit with a peptide corresponding to resi-
dues 291–301ofthe GPC3protein.To determineIGF-1Rphosphorylation,600
lg of cell extract was immunoprecipitated with anti-IGF-1Rb and then blotted
with PY20 or blotted with anti-phospho-IGF-1Rb.
Intact cell IGF-1R phosphorylation
Subconﬂuent cells in 24-well plates were serum starved in serum-free medium
for 24 h and then incubated either with or without IGF-II (20 ng/ml) for 5, 15,
30 or 60 min at 37C. The cells were washed rapidly with ice-cold phosphate-
buffered saline then lysed in the lysis buffer (20 mM HEPES N-(Hydroxye-
thyl)piperazine-N’-(2-ethanesulfonic acid), pH 7.5, NP40 1%, NaCl 150 mM,
NaF 10 mM, glycerol 10%, Na4P2O7 10 mM, sodium vanadate 0.1 mM,
b-glycerol phosphate 2 mM and protease inhibitor cocktail). The amount of
phospho-IGF-1 receptor was determined by immunoblotting with anti-phos-
pho-IGF-1Rb and then reprobed by anti-IGF-1Rb.
Heparitinase digestion
Cell extract was ﬁrst immunoprecipitated with anti-CC3. The precipitates were
washed for three times with digestion buffer [50 mM HEPES, pH 7.0, 100 mM
NaCl,1mMCaCl2,5 0lghumanalbumin,2mMphenylmethylsulfonylﬂuoride,
5 mM ethylenediaminetetraacetic acid and protease inhibitor cocktail (Roche,
Basel, Switzerland)] and treated with 2.5 mU of heparitinase (Seikagaku, Tokyo,
Japan) for 2.5 h at 37C. Western blot analysis was then done using 1G12.
RNA interference
Forthegpc3 RNAinterference, HuH-7cellswere transfectedwith1 lg ofgpc3
small hairpin RNA (shRNA) (TGCTGTTGACAGTGAGCGACCCAA-
CATGCTGCTCAAGAAATAGTGAAGCCACAGATGTATTTCTTGAGCAG-
CATGTTGGGCTGCCTACTGCCTCGGA) or an enhanced green ﬂuorescent
proteins shRNA (control) in pSM2c vector (purchased from Open Biosystems,
Huntsville, AL). For IGF-II RNA interference, chemically synthesized,
double-stranded small interfering RNA (siRNA)s, with 19 nt duplex RNA
and 2 nt dTdT overhangs were purchased from Ambion. The sequence was
sense primer, GGUUCCAUCCCGAAAAUCUtt and antisense primer,
AGAUUUUCGGGAUGGAACCtg. The action of IGF-II siRNA was ﬁrst
proved in HEK293 cells. The effect of IGF-II knockdown was done by experi-
ments of HuH-7 cell transfection.
Determination of cell growth and colony formation
NIH3T3 cells (1   104) or PLC-PRF-5 stable cells were plated in 35 mm
dishes or 12-well plates in regular medium. On the next day, the cultures were
changed to serum-free medium. Viable cells were counted at 48 h intervals.
shRNA to gpc3 was performed in HuH-7. HuH-7 cells (1   105) were trans-
fected and plated in six-well plates and then selected with 1 lg/ml puromycin
for 14 days. Colonies were visualized by Giemsa stain in HuH-7. For IGF-II
interference, chemically synthesized double-stranded siRNA to IGF-II were
transfected into 4   104 HuH-7 cells according to the manufacturer’s instruc-
tion. On the next day, the cultures were changed to serum-free medium. Cells
were counted at 48 h intervals for 6 days.
Soft agar assay
Anchorage-independent growth assay was done on three-layer soft agar in six-
well ﬂat-bottomed plates for 30 days. Colonies were then stained with 0.05%
p-iodonitrotetrazolium violet and counted by inverted microscopy.
Glutathione S-transferase pull-down assay
The IGF-II complementary DNA, cloned by primers IGF-II-F (CGGGATC-
CATGGGAATCCCAATGGGGAA) and IGF-II-ls-R (GGAATTCCTTCC-
GATTGCTGGCCATCTCT), was inserted into pGEX4T1 vector for the
production of GST-fusion protein. GST-IGF-II was expressed in Escherichia
coli and puriﬁed. For the pull-down assay, cell extract from pcDNA-gpc3-
transfected HEK293T cells was prepared in lysis buffer (10 mM Tris–HCl,
pH7.4, 100 mM NaCl and 2.5 mM MgCl2) with 0.1% Triton X-100 and then
incubated with GST-IGF-II at 4C for 1 h. Proteins bound to the GST beads
were analyzed by western blot.
Coimmunoprecipitation detection of the GPC3–IGF-1R complex
HEK293Tcells were transfected with pcDNA-gpc3. The transfected cells were
lysed in HNTG buffer (20mM Hepes, 100mM sodium chloride, 0.05% triton
X-100, 10% glycerol) (35) and precleaned. Immunoprecipitation (IP) was done
with anti-CC3, and western blot analysis was donewith either anti-IGF-1Rb or
1G12.
Results
Establishment of GPC3-expressing NIH3T3 cell lines
NIH3T3 cells do not have intrinsic GPC3 expression and therefore we
expressed GPC3 in these cells to see if GPC3 could confer additional
phenotypes (36). For the detection of GPC3 and to trace its posttrans-
lational modiﬁcation, a GFP tag was added to the C-terminus of GPC3
(GPC3-GFP).GPC3isa glycosyl-phosphatidylinositol-linkedheparan
sulfate proteoglycan, and its C-terminal signal sequence will be re-
moved when glycosyl-phosphatidylinositol is added, resulting in a 65
kDa core protein which will be glycanated. The 65 kDa core protein
can be further cleaved by a furin-like convertase into a 40 kDa protein.
After transient transfection with pgpc3-GFP, nascent GPC3 could
be detected by anti-GFP, 1G12, and anti-CC3 (Figure 1A, lanes 2, 4
and 6, arrow), whereas the 65 kDa core protein (arrowhead) and the
glycanated forms (bracket) could be detected by 1G12 and anti-CC3
(lanes 4 and 6). The 40 kDa protein (asterisk) could be detected only
by anti-CC3 (lane 6) (14). Membrane anchoring of the expressed
GPC3 protein was also evident (supplementary Figure, panel B is
available at Carcinogenesis Online). Therefore, the GFP tag did not
interferewiththe C-terminal processingof GPC3. After selectionwith
G418, two stable clones GPC3-60 and GPC3-65 were isolated. gpc3
mRNA was expressed in these positive clones (Figure 1B), and the
expression of GPC3 protein could be detected by IP and heparitinase
digestion (Figure 1C). Since pEGFP-N1 is toxic to the cells, cells trans-
fected with pcDNA3.1 (þ) myc-his were used as vector control (37).
Oncogenecity of the GPC3-expressing NIH3T3 cells
Compared with the parental NIH3T3 cells, GPC3-60 and GPC3-65
cells exhibited large nuclei with frequent multinucleation (Figure 1Da
and b), but grew at a normal speed in regular medium. However, when
cells were grown in serum-free medium, these GPC3-expressing cells
kept on proliferating while the control cells died gradually (Figure
1E). Both GPC3-60 and GPC3-65 cells formed colonies on soft agar
after 30 days of culture (Figure 1F), but the parental NIH3T3 cells or
the vector control cells could not (Table I). Therefore, NIH3T3 cells
gain oncogenecity after the expression of GPC3.
Role of GPC3 in HCC cell oncogenecity
To explore the role of GPC3 in HCC cell oncogenecity, we ﬁrst over-
expressed GPC3 inGPC3-low-expressingPLC-PRF-5 cells (Figure 2A).
After gaining the expression of GPC3, PLC-PRF-5 cells grew faster
than the parental cells in serum-free medium (Figure 2B). On the
other way, we knocked down GPC3 with shRNA in GPC3-high-
expressing HuH-7 cells (Figure 2C). The results revealed that HuH-7
cells transfected with gpc3 shRNA showed poorer colony formation
than cells transfected with the control shRNA (Figure 2D). These
results indicate that the expression of GPC3 increases the oncogenec-
ity of HCC cells.
W.Cheng et al.
1320GPC3 is associated with IGF-II and IGF-1R through its proline-rich
region
It has been reported that GPC3 binds to IGF-II (19,20). Both NIH3T3
cells and hepatoma cell lines HuH-7 have beenshowntoproduce IGF-
II (38,39). Using reverse transcription–polymerase chain reaction
method, we found that IGF-II expression was high in cell lines in-
cluding NIH3T3 and HuH-7 and was low in the HA22T/VGH cells
(Figure 3A). Therefore, we tested the interactions between GPC3,
IGF-II and IGF-1R (Insulin-like growth factor 1 receptor, one kind
of receptor for IGF-II). In GST pull-down assay, GPC3 expressed in
HEK293T cells could be pulled down by GST-IGF-II (Figure 3B, lane
6). GPC3 contains a proline-rich region located at residues 25–30,
Fig. 1. GPC3 promotes cell growth in NIH3T3 cells. (A) Transient expression of GPC3 in HEK293T cells. Cells were transfected with pgpc3-GFP, and 48 h later,
cytosolic extracts were analyzed by western blot using anti-GFP (lanes 1 and 2), 1G12 (lanes 3 and 4) or anti-CC3 (lanes 5 and 6). Molecular weight markers are
indicated on the left. The bracket indicates glycanated GPC3 proteins; the arrow indicates the nascent GPC3 protein; the arrowhead indicates the 65 kDa core
protein and the asterisk indicates the 40 kDa convertase-cleaved fragment. (B) Reverse transcription–polymerase chain reaction analysis of gpc3 mRNA in stable
lines. Lane 1, the parental NIH3T3 cells; lane 2, vector control cells; lane 3, GPC3-60 cells; lane 4, GPC3-65 cells and lane 5, positive control (þ). Mouse actin
was served as the RNA loading control. (C) Expression of GPC3 protein in stable lines. Six hundred micrograms of cytosolic extracts were immunoprecipitated
with anti-CC3, digested by heparitinase and then blotted with 1G12. Lane 1, the parental cells; lane 2, GPC3-60 cells and lane 3, GPC3-65 cells. The open arrow
indicates the GPC3 core protein, and the black arrow indicates the antibody heavy chain. (D) Morphology of the cells. GPC3-60 and GPC3-65 cells revealed
increased nucleus-to-cytoplasm (N/C) ratio and multinucleation in Papanicolaou stain (a and b). Parental and vector control cells were shown as a comparison
(c andd).(E) Growth rateofthe GPC3-expressingcells in serum-freemedium.Cells wereseededin 35 mmplatesin triplicateand culturedin Dulbecco’smodiﬁed
Eagle’s medium without serum. Cells were harvested at 48 h intervals and were counted in triplicates. (F) Colony formation in soft agar was observed for
GPC3-expressing line GPC3-60 and GPC3-65 (a and b), but not for the parental or vector control cells (c and d).
Table I. Anchorage-independent growth of GPC3-expressing NIH3T3 cells
Lines Number of colonies
per plate
a
Sizes of colonies
(lm)
GPC3-60 46 ± 9
b  40
GPC3-65 55 ± 6
b  100
NIH3T3 0 —
Vector control 0 —
aColonies in soft agar were counted directly using an inverted microscope on
day 30.
bP , 0.0001 versus the parental and control cells, t-test.
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1321which might be important for protein–protein interaction. GPC3
mutated in these prolines (P25-29A), when expressed in cells, could
be localized to the cell surface (supplementary Figure, panel D is
available at Carcinogenesis Online) and glycanated (Figure 3B, lane
4). However, P25-29A did not possess the ability to bind IGF-II
(Figure 3B, lane 8). We next tested the requirement of convertase
digestion for GPC3 interaction with IGF-II. The convertase-resistant
mutant RR / AA revealed cell membrane anchorage (supplementary
Figure, panel C is available at Carcinogenesis Online) and glycana-
tion (Figure 3B, lane 3) (34), but had very low afﬁnity to GST-IGF-II
(Figure 3B, lane 7). Therefore, convertase digestion is required for
GPC3 to interact with IGF-II.
The interaction between GPC3 and IGF-1R was investigated by co-
IP. HEK293T cells were ﬁrst transfected with pcDNA-gpc3 or P25-
29A and serum starved. IP was performed with anti-CC3. The results
revealed that IGF-1R could be brought down by anti-CC3 (Figure
3C), whereas P25-29A lost the ability to interact with IGF-1R (Figure
3C, lane 4). Therefore, these results indicate that GPC3 has speciﬁc
interaction with both IGF-II and IGF-1R.
Phosphorylated IGF-1R interacts with GPC3
P h o s p h o r y l a t i o no fI G F - 1 Ro c c u r su p o nl i g a t i o nb yg r o w t hf a c -
tors. We then checked if IGF-1R phosphorylation could be acti-
vated by GPC3. In GPC3-expressing NIH3T3 cells, IGF-1R
immunoprecipitated by anti-IGF-1Rb could be detected by PY20
(Figure 4A). It was noted that GPC3o v e r e x p r e s s i o na l s ou p r e g u -
lated the unphosphorylated IGF-1R. Since phosphorylated IGF-1R
was present in HuH-7 cells, we checked the status of IGF-1R in
these cells after GPC3 knockdown. The results revealed that both total
and phosphorylated IGF-1R proteins decreased in amount when cells
were treated with gpc3 shRNA (Figure 4B). The mechanism for the
downregulation of total IGF-IR by GPC3 knockdown is not known,
but this phenomenon suggests both the importance and the complexity
of the regulation of the IGF-1R pathway by GPC3.
We next looked for evidence if GPC3 enhances IGF-II-mediated
IGF-1R activation. We transfected GPC3 or its mutants in HEK293
cells and then treated the cells with IGF-II. IGF-II induced IGF-1R
phosphorylation, which peaked at the 30th min in control cells, and the
phosphorylation declined thereafter (Figure 4C, vector). In pcDNA-
gpc3-transfected cells, IGF-II triggered a faster and stronger phosphor-
ylation of IGF-1R and the phosphorylation also sustained longer.
RR / AA or P25-29A either demonstrated a later (RR / AA)
and/or weaker (RR / AA and P25-29A) responses (Figure 4C).
Therefore,GPC3activatestheIGF-signalingpathwayinaspeciﬁcway.
Phosphorylation of ERK by GPC3
Lastly, we checked if GPC3 could activate the downstream mito-
genic pathway. In western blot analysis, the levels of total ERK in
the parental NIH3T3 cells, 12-O-tetradecanoylphorbol 13-acetate
treatment HEK293 cells or GPC3 expression NIH3T3 cells were
equal (Figure 5A). 12-O-tetradecanoylphorbol 13-acetate induced
prominent ERK phosphorylation in HEK293 cells (Figure 5A, lane
2). Phospho-ERK was barely visible in the parental NIH3T3 cells,
but was abundant in GPC3-expressing cell lines GPC3-60 and
Fig. 2. Role of GPC3 in HCC cell oncogenecity. (A) GPC3 expression in PLC-PRF-5 cells. Mixed cultures of stable cell linewere obtained by transfecting pgpc3-
GFP or vector control into PLC-PRF-5 cells. Cell lysates were analyzed by western blot with 1G12. The bracket indicates glycanated GPC3 proteins; the arrow
indicates the nascent GPC3 protein and the arrowhead indicates the 65 kDa core protein. (B) Growth rate of the PLC-PRF-5 stable cells. Cells (1   104) were
seeded in 12-well plates in triplicate and cultured in Dulbecco’s modiﬁed Eagle’s medium without serum. Cells were harvested at 48 h intervals and were counted
in triplicates. (C) GPC3 knockdown in HuH-7 cells. Cells were transfected with gpc3 shRNA or control vector (shRNA-EGFP), and 48 h later, cell extracts were
analyzed by western blot with 1G12. The bracket indicates glycanated GPC3 proteins, and the arrowhead indicates the 65 kDa core protein. (D) Colony-forming
assays for HuH-7 cells. Cells were transfected with either shRNA-EGFP (control) or shRNA-GPC3 cells.
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1322GPC3-65 (Figure 5A, lanes 3 and 4). In the GPC3-high-expressing
HuH-7 cells, ERK phosphorylation was high, but phospho-ERK de-
creased when GPC3 was knocked down by gpc3 shRNA (Figure
5B). In the GPC3-low-expressing PLC-PRF-5 and HA22T/VGH
cells, stable expression of GPC3 caused the elevation of phospho-
ERK, but mutants RR / AA or P25-29A had much less effects
(Figure 5C and D). Serum starvation for the HA22T/VGH cells
was done in 0.5% serum because in 0% serum no ERK phosphory-
lation could be seen. This could be due to the low IGF-II expression
in HA22T/VGH cells (Figure 3A).
We further demonstrated that ERK phosphorylation was dependent
on the presence of IGF-II. We ﬁrst selected a proper IGF-II siRNA by
Fig. 3. GPC3 interacts with IGF-II and IGF-1R. (A) Reverse transcription–polymerase chain reaction analysis of IGF-I and IGF-II gene expressions in different
cell lines. Total RNA was isolated from HEK293, HEK293T, PLC-PRF-5, HuH-7, Hep3B, HA22T/VGH and NIH3T3 cells and complementary DNA was
synthesized using reverse transcriptase. As a negative control, the same RNAs were incubated in the absence of enzyme in the reverse transcription reaction.
Polymerasechain reactionwas thendonewithspeciﬁc primers.Actin wasserved as the RNAloading control.(B) Interaction of overexpressed GPC3 proteins with
IGF-II. Wild-type GPC3 (WT-GPC3), RR / AA or P25-29A expression plasmid was transfected into HEK293T cells. After serum starvation for overnight, cells
were harvested and subjected for GST pull-down assay with either GST-IGF-II or GSTand then analyzed by western blot with 1G12. Lanes 1–4 represent 5% of
cell extract used in the pull-down experiment (lysate). (C) Interaction between GPC3 and IGF-1R. HEK293T cells were transfected with either pcDNA-gpc3 or
P25-29A. The cell lysates were then immunoprecipitated with anti-CC3 or IgG and blotted with anti-IGF-1R or 1G12. Five percent of cell extracts were analyzed
in parallel (input). The bracket indicates glycanated GPC3.
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1323transfecting HEK293 cells (Figure 5E). In HuH-7 cells treated with
IGF-II siRNA, we could demonstrate that the level of phospho-ERK
decreased (Figure 5F) and those treated cells revealed a decreased
growth speed in serum-free medium (Figure 5G). Therefore, the ac-
tivation of intracellular mitogenic pathway requires the presence of
both IGF-II and GPC3.
Discussion
In this article, we demonstrate that GPC3 can bind to both IGF-II and
IGF-1R through its proline-rich region. GPC3 binding to IGF-II acti-
vates IGF-1R and then triggers a phosphorylation cascade including
IGF-1R itself and ERK. These processes confer oncogenecity to
NIH3T3 and hepatoma cells PLC-PRF-5, whereas the removal of
GPC3 decreases the oncogenecity of HuH-7 cell lines. The pathogen-
esis of HCC hasbeen known toinvolvep53 (40), b-catenin (41), TGF-
b (42) and the retinoblastoma gene (43). p53 mutation occurs in
one-third of HCC (40,44); b-catenin mutation is found in 13.1% of
HCC (41) and the activation of canonical Wnt-signaling pathway
happens in 18% of HCC (45). The involvement of GPC3 in HCC is
more recently recognized that overexpression of GPC3 can be found
in 70% of HCC (4). And now in this study, we discover the mecha-
nisms that led to GPC3-mediated oncogenesis.
It is very interesting that GPC3 interacts with both IGF-II and its
receptor IGF-1R.This may suggests that GPC3 joins a multiprotein
complex, which is composed of the ligand, receptor, GPC3, and prob-
ably other proteins. The interaction between the proteins in the com-
plexprobably involvesheparan sulfate. However, herewe showed that
speciﬁc protein–protein interaction through the proline-rich region of
the GPC3 protein is also required. Protein–protein interaction through
the multiproline residues has been shown for the histidine proline-rich
glycoprotein (46). Histidine proline-rich glycoprotein is an abundant
plasma protein. It binds with high afﬁnity to FGF-2-stimulated human
umbilical vein endothelial cells and immobilizes tropomyosin via the
histidine proline-rich domain (46). Moreover, proper processing of
GPC3 is required for its function. In the current study, convertase
digestion is necessary for GPC3 to activate the IGF-signaling
pathway. In a previous study, convertase is required for GPC3-medi-
ated regulation of the Wnt-signaling pathway (34). All these data
suggest a speciﬁc protein–protein interaction for GPC3 function, be-
sides the non-speciﬁc interaction through heparan sulfate.
The activation of IGF-1R and the downstream signaling pathway
well explains the role of GPC3 in oncogenesis. The IGF-signaling
pathway plays a pivotal role in cell growth. Overexpressions of IGF-
II, IGF-1R and insulin receptor substrate-1 have been described in
human cancers (30,47–50). ERK is known to mediate IGF-II-induced
gene expression, cell invasion and apoptosis protection (51,52). ERK
has also been shown to contribute to the multistep hepatocarcinogen-
esis (53). Although GPC3 knockout mice showed no signiﬁcant
change of IGF-1R or insulin receptor substrate-1 in whole embryo
extracts (54), cell growth in GPC3-transgenic mice is promoted in the
liver (5). Therefore, GPC3 may have a more prominent role in liver
cancers like HCC.
In this study, we not only demonstrate the activation of the IGF-
signaling pathway by GPC3 but also more importantly give a direct
evidence for GPC3-mediated oncogenesis. GPC3 confers NIH3T3
cells a full cancer cell phenotype including the ability to grow in
serum-free medium and to form colonies in soft agar. It is also striking
Fig. 4. GPC3 enhances the IGF-II-triggered IGF-1R phosphorylation. (A) IGF-1R phosphorylation in GPC3-expressing NIH3T3 stable lines. Cells were serum
starved and 600 lg of cell extracts were immunoprecipitated with anti-IGF-1Rb, followed by western blot with PY20. IGF-1R was phosphorylated. Twenty
micrograms of total cell extracts were analyzed with anti-tubulin as an equal loading control. (B) IGF-1R phosphorylation in HuH-7 cells. Cells were transfected
with control or gpc3 shRNA and serum starved. Whole-cell extracts were then subjected to immunoblot with anti-phospho-IGF-1R and then reblotted with anti-
IGF-1Rb. Phosphorylated IGF-IR was decreased by gpc3 shRNA in HuH-7 cells. (C) IGF-II-triggered IGF-1R phosphorylation in HEK293 cells. Either wild-type
GPC3 (WT-GPC3), RR / AA or P25-29Awas expressed in HEK293 cells. Transiently transfected cells were serum starved and then treated with IGF-II (20 ng/
ml) for 5, 15, 30 or 60 min at 37C, followed by western blot probed with anti-phospho-IGF-1Rb and reprobed with anti-IGF-1R. GPC3 expression was shown in
parallel.
W.Cheng et al.
1324to see the loss of oncogenecity by knocking down GPC3 by shRNA in
HCC cells. Therefore, GPC3 could be a new target in cancer therapy
in the future.
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